New obesity drug combo shows promise in Long-Term weight loss study

NCT ID NCT06780449

Ongoing Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 25 times

Summary

This study tests a new medicine, CagriSema, for weight loss in 400 adults with severe obesity (BMI 35 or higher). Participants receive either CagriSema or a placebo for 2 years, then some switch to CagriSema or reduce their dose for another year. The goal is to see how much weight is lost and how safe the medicine is over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

APDP - Associação Protectora dos Diabéticos de Portugal

Lisbon, 1250-189, Portugal
Aarhus Universitetshospital, Steno Diabetes Center Aarhus

Aarhus, 8200, Denmark
Addenbrooke's Hospital_Cambridge

Cambridge, CB2 0QQ, United Kingdom
Aintree University Hospital

Liverpool, L9 7AL, United Kingdom
Alpha Recherche Clinique - Lebourgneuf

Québec, G2J 0C4, Canada
CHU Helora - Hôpital de Mons - Site Constantinople

Mons, 7000, Belgium
CUF Descobertas

Lisbon, 1998-018, Portugal
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie

Brussels, 1200, Belgium
Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States
Dr. M.B. Jones Inc

Victoria, British Columbia, V8V 4A1, Canada
East West Medical Research Institute_Honolulu

Honolulu, Hawaii, 96814, United States
Gentofte Hospital - Center for Klinisk Metabolisk Forskning

Hellerup, 2900, Denmark
Holston Medical Group_Bristol

Bristol, Tennessee, 37620, United States
Hospital Cuf Descobertas S.A.

Lisbon, 1998-018, Portugal
Hospital Luz Arrabida, S.A.

Vila Nova de Gaia, 4400-346, Portugal
Hvidovre Hospital Endokrinologisk forsknings afsnit 159

Hvidovre, 2650, Denmark
Joint Clinical Research Facility - Swansea

Swansea, SA2 8PP, United Kingdom
L-MARC Research Center

Louisville, Kentucky, 40213, United States
Musgrove Park Hospital

Taunton, TA1 5DA, United Kingdom
North Texas Endocrine Center

Dallas, Texas, 75231, United States
Nova Scotia Health Authority

Halifax, Nova Scotia, B3H 2Y9, Canada
Premier Clinical Trial Research Network (PCTRN)

Hamilton, Ontario, L8L 5G4, Canada
Royal London Hospital - Blizard Institute

London, E1 2AJ, United Kingdom
Sjællands Universitetshospital, Køge - Medicinsk Afdeling

Køge, 4600, Denmark
Southmead Hospital

Bristol, BS10 5NB, United Kingdom
Spartanburg Medical Research

Spartanburg, South Carolina, 29303, United States
StudyMetrix Research LLC

City of Saint Peters, Missouri, 63303, United States
Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden

Esbjerg, 6700, Denmark
ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

Senhora Da Hora, Matosinhos, Matosinhos, 4464-513, Portugal
UZ Leuven - Endocrinology

Leuven, 3000, Belgium
UZA - UZ Antwerpen - Department of Endocrinology

Edegem, 2650, Belgium
Unidade Local de Saude de Sao Joao E.P.E

Porto, 4200-319, Portugal
University Hospital Coventry - WISDEM Centre

Coventry, CV2 2DX, United Kingdom
Valley Clinical Trials

Covina, California, 91723, United States
Washington Cntr Weight Mgmt

Arlington, Virginia, 22206, United States
Yale University School Of Medicine

New Haven, Connecticut, 06519, United States

Conditions

Explore the condition pages connected to this study.

OBESITY